Regeneron Pharmaceuticals will share in development of Tessera Therapeutics’ TSRA-196, a Phase 1-ready gene-editing therapy for alpha-1 antitrypsin deficiency (AATD). Other companies developing genetic medicines for this rare disease include Beam Therapeutics, Wave Life Sciences, Korro Bio, and AIRNA.
Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed their respective pivotal studies in the disorder earlier this year.
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
November has seen a slew of executive hires, promotions and layoffs across the healthcare industry. For instance, the Joint Commission, Silicon Valley Bank and Regard named new executives. There were also layoffs at organizations including Oak Street Health, Providence and Optum.
Oura has evolved from a sleep-focused wellness startup into a company getting deeper and deeper into chronic disease management and healthcare integration. Ricky Bloomfield, the company’s chief medical officer, said Oura wants to integrate more of its data into healthcare workflows — in ways that are clinically meaningful, not burdensome, for physicians, he emphasized.
Ostro’s health AI literacy course set a Guinness World Record this week, with 698 participants completing the 30-minute online lesson in 24 hours. The course offers practical training on generative AI, compliance and human-in-the-loop processes to improve understanding across the healthcare and life sciences industries.
Function Health raised a $298 million Series B round, pushing its valuation into unicorn territory at $2.5 billion. The Austin-based startup offers subscribers access to more than 160 lab tests, as well as imaging.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Johnson & Johnson is acquiring Halda Therapeutics for its lead program, a drug that recently posted encouraging Phase 1 data in advanced prostate cancer. This drug comes from a proprietary Halda platform technology that yields oral small molecules offering a novel mechanism for killing cancer cells.
Check out news from Oral Genome, Beacon Biosignals, Modulight Therapeutics, No Barrier, and Lab Central.
Iambic’s latest financing follows the presentation of data for its breast cancer drug during the recent European Society of Medical Oncology conference. Our financing roundup includes capital raised by startups developing novel therapies immunology, metabolic disorders, genetic diseases, and more.
The Digital Medicine Society launched a new initiative — it seeks to establish a roadmap for how technology can support older adults who want to age safely at home. The project will bring together health systems, home health agencies and tech companies to develop products, policy guidance and case studies for scalable home care.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Startups in the ambient documentation space are moving beyond simple scribing to tools that can handle tasks like intake, coding and care coordination, according to Heidi Health CEO Tom Kelly. Standing out in this crowded market is a challenge, and companies’ success will hinge on creating products clinicians actually want to use, he added.
HumoTech has developed a robotic platform that lets patients quickly try multiple prosthetic or exoskeleton options in a clinic, using both objective data and patient feedback to identify the best fit. The technology aims to reduce device abandonment and improve outcomes.
Check out news from Oral Genome, Amae Health, Hepta, and more.
Braveheart Bio is preparing to advance to Phase 3 testing in obstructive hypertrophic cardiomyopathy, or oHCM. The startup says its small molecule could have safety advantages over Camzyos, a Bristol Myers Squibb capsule projected to become a blockbuster seller in this indication.
AI continues to dominate digital health funding, but investors and health systems are demanding proof that these tools actually save money — and quickly. AI startups without clear, measurable ROI are finding it harder to stand out, explained Vig Chandramouli, partner at Oak HC/FT.